» Articles » PMID: 36591229

Reinventing the Human Tuberculosis (TB) Granuloma: Learning from the Cancer Field

Overview
Journal Front Immunol
Date 2023 Jan 2
PMID 36591229
Authors
Affiliations
Soon will be listed here.
Abstract

Tuberculosis (TB) remains one of the deadliest infectious diseases in the world and every 20 seconds a person dies from TB. An important attribute of human TB is induction of a granulomatous inflammation that creates a dynamic range of local microenvironments in infected organs, where the immune responses may be considerably different compared to the systemic circulation. New and improved technologies for quantification and multimodal imaging of mRNA transcripts and protein expression at the single-cell level have enabled significantly improved insights into the local TB granuloma microenvironment. Here, we review the most recent data on regulation of immunity in the TB granuloma with an enhanced focus on selected studies that enable spatial mapping of immune cell phenotypes and functions. We take advantage of the conceptual framework of the cancer-immunity cycle to speculate how local T cell responses may be enhanced in the granuloma microenvironment at the site of infection. This includes an exploratory definition of "hot", immune-inflamed, and "cold", immune-excluded TB granulomas that does not refer to the level of bacterial replication or metabolic activity, but to the relative infiltration of T cells into the infected lesions. Finally, we reflect on the current knowledge and controversy related to reactivation of active TB in cancer patients treated with immune checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4. An understanding of the underlying mechanisms involved in the induction and maintenance or disruption of immunoregulation in the TB granuloma microenvironment may provide new avenues for host-directed therapies that can support standard antibiotic treatment of persistent TB disease.

Citing Articles

How macrophage heterogeneity affects tuberculosis disease and therapy.

Russell D, Simwela N, Mattila J, Flynn J, Mwandumba H, Pisu D Nat Rev Immunol. 2025; .

PMID: 39774813 DOI: 10.1038/s41577-024-01124-3.


Editorial: The role of transcriptional regulation in mycobacterium physiology.

Liu S, Song N, Subbian S Front Cell Infect Microbiol. 2024; 14:1483263.

PMID: 39286814 PMC: 11402902. DOI: 10.3389/fcimb.2024.1483263.


Novel Prodrug Strategies for the Treatment of Tuberculosis.

Kim C, Jose J, Hay M, Choi P Chem Asian J. 2024; 19(23):e202400944.

PMID: 39179514 PMC: 11613820. DOI: 10.1002/asia.202400944.


Drinking Water Microbiota, Entero-Mammary Pathways, and Breast Cancer: Focus on Nontuberculous Mycobacteria.

Maranha A, Alarico S, Nunes-Costa D, Melo-Marques I, Roxo I, Castanheira P Microorganisms. 2024; 12(7).

PMID: 39065193 PMC: 11279143. DOI: 10.3390/microorganisms12071425.


Dual neutrophil subsets exacerbate or suppress inflammation in tuberculosis via IL-1β or PD-L1.

Doz-Deblauwe E, Bounab B, Carreras F, Fahel J, Oliveira S, Lamkanfi M Life Sci Alliance. 2024; 7(7.

PMID: 38803236 PMC: 11109925. DOI: 10.26508/lsa.202402623.


References
1.
Tay R, Richardson E, Toh H . Revisiting the role of CD4 T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther. 2020; 28(1-2):5-17. PMC: 7886651. DOI: 10.1038/s41417-020-0183-x. View

2.
Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

3.
Khan N, Vidyarthi A, Amir M, Mushtaq K, Agrewala J . T-cell exhaustion in tuberculosis: pitfalls and prospects. Crit Rev Microbiol. 2016; 43(2):133-141. DOI: 10.1080/1040841X.2016.1185603. View

4.
Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

5.
Ulrichs T, Kaufmann S . New insights into the function of granulomas in human tuberculosis. J Pathol. 2005; 208(2):261-9. DOI: 10.1002/path.1906. View